NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

In the past week, the Danish biotech and healthcare stocks rose 7.9%, driven by 7 stocks with a return of more than 10%. Curasight, in particular, rose 65% following the completion of their rights issue, raising DKK 47 million. Moreover, Acarix’s CEO bought shares, and Danske Bank is eyeing a more than 3x potential in Zealand Pharma.

Latest news for the Danish biotech companies

Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.

Acarix’s CEO bought shares worth SEK 200,000

Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.

No news in the past week

Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials

Biosergen released its Q1 results and highlighted its successful completion of the second patient cohort in its BSG005 proof-of-concept clinical trial, targeting life-threatening fungal infections.

Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.

No news in the past week

Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).

Curasight announced the outcome of their rights issue, bringing in a total of DKK 47 million. The rights issue was subscribed to approximately. 42.4%, while the rest was subscribed by guarantors. Based on the outcome, Curasight will receive approximately DKK 47 million from the rights issue before costs and repayment of the bridge loan to Fenja Capital II A/S.

DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.

DanCann Pharma released its Q1 results with a drop in revenue.

Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.

Evaxion announced the dosing of its first patient in the phase 2 trial exploring the full potential of AI-designed cancer vaccines EVX-01.

ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.

No news in the past week

Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.

No news in the past week

Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.

Deutsche Bank lowered its price target from DKK 1,900 to 1,750, and Redburn to DKK 2,700 from 2,750.

Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.

No news in the past week

Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.

Initiator Pharma has this morning announced a rights issue of MSEK 56, which is 86% secured.

IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.

No news in the past week

Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.​

No news in the past week

Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.

Saniona appointed Johnny Stilou as their new CFO.

Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges, thus, financial stability is the main driver for the stock price.

No news in the past week

SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance

No news in the past week

ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.

No news in the past week

Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts. ​

No news in the past week

Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in its late-stage pipeline and partnerships are key stock price influencers.

Deutsche Bank lowered its price target from DKK 750 to 485, while Danske Bank set its price target of DKK 400, and noted the stock has the potential to go to DKK 1,350.

2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.

2cureX announced its first direct-to-patient IndiTreat® test under “Operation Twin Code” Strategy

The latest share price developments for the Danish biotech stocks

On average, the Danish biotech and healthcare stocks rose 7.9% driven by 7 stocks with a double-digit return. As seen before, many of the high-performing stocks in the past week did not report any news. Curasight announced it raised DKK 47 million in its rights issue. However, the company was already guaranteed DKK 47 million, so the news can not explain why the stock took off. Furthermore, Genmab and Zealand Pharma got positive price targets with Danske Bank even eying a 3x potential in Zealand Pharma. Acarix’s CEO bought shares, and multiple companies released its Q1 earnings with comments on their current development such as Biosergen, highlighting the completion of its second patient cohort with BSG005.

Overview of share price development in the past week, year-to-date, and the last twelve months

DanCann Pharma does not appear on the list due to data issues.

Aptahem AB is raising capital; you can participate!

Aptahem AB is a Swedish clinical-stage biotech company developing RNA-based drugs for the treatment of sepsis and inflammatory diseases. Sepsis affects 50 million people every year, of which 11 million die. Aptahem’s lead drug candidate, Apta-1, has already demonstrated good safety and anti-inflammatory properties in a Phase I trial. The company is now raising SEK 9.7 million to continue the development of Apta-1 in preparation for a Phase II trial to demonstrate proof-of-concept. The last day of subscription is May 30, 2025.